>2013 8 e79781 10.1371/journal.pone.0079781 24236158 Butler LM Agus DB Scher HI Higgins B Rose A Cordon-Cardo C Thaler HT Rifkind RA Marks PA Richon VM Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo Cancer Res 2000 60 5165 70 11016644 Gaupel A.C Begley T Tenniswood M High throughput screening identifies modulators of histone deacetylase inhibitors BMC Genomics 2014 15 528 10.1186/1471-2164-15-528 24968945 West AC Johnstone RW New and emerging HDAC inhibitors for cancer treatment J Clin Invest 2014 124 30 39 10.1172/JCI69738 24382387 Huang YC Huang FI Mehndiratta S Lai SC Liou JP Yang CR Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis Oncotarget 2015 6 18590 601 10.18632/oncotarget.4068 26087180 Ha K Fiskus W Choi DS Bhaskara S Cerchietti L Devaraj SG Shah B Sharma S Chang JC Melnick AM Hiebert S Bhalla KN Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells Oncotarget 2014 5 5637 50 10.18632/oncotarget.2154 25026298 Yang Y Fiskus W Yong B Atadja P Takahashi Y Pandita TK Wang HG Bhalla KN Acetylated HSP70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy Proc Natl Acad Sci USA 2013 110 6841 46 10.1073/pnas.1217692110 23569248 Haaland I Opsahl JA Berven FS Reikvam H Fredly HK Haugse R Thiede B McCormack E Lain S Bruserud O Gjertsen BT Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia Mol Cancer 2014 13 116 10.1186/1476-4598-13-116 24885082 Kim HJ Bae SC Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs Am J Transl Res 2011 3 166 79 21416059 Straus DJ Hamlin PA Matasar MJ Lia Palomba M Drullinsky PR Zelenetz AD Gerecitano JF Noy A Hamilton AM Elstrom R Wegner B Wortman K Cella D Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation Br J Haematol 2015 168 663 70 10.1111/bjh.13195 25316653 Kirschbaum M Gojo I Goldberg SL Bredeson C Kujawski LA Yang A Marks P Frankel P Sun X Tosolini A Eid JE Lubiniecki GM Issa JP A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome Br J Haematol 2014 167 185 93 10.1111/bjh.13016 25040094 Gueugnon F Cartron PF Charrier C Bertrand P Fonteneau JF Gregoire M Blanquart C New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells Oncotarget 2014 5 4504 15 10.18632/oncotarget.2056 24980825 Tu Y Hershman DL Bhalla K Fiskus W Pellegrino CM Andreopoulou E Makower D Kalinsky K Fehn K Fineberg S Negassa A Montgomery LL A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer Breast Cancer Res Treat 2014 146 145 52 10.1007/s10549-014-3008-5 24903226 Han JY Lee SH Lee GK Yun T Lee YJ Hwang KH Kim JY Kim HT Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer Cancer Chemother Pharmacol 2015 75 475 83 10.1007/s00280-014-2664-9 25552401 Sun S Han Y Liu J Fang Y Tian Y Zhou J Ma D Wu P Trichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cells Plos One 2014 9 e91610 10.1371/journal.pone.0091610 24626188 Ruefli AA Ausserlechner MJ Bernhard D Sutton VR Tainton KM Kofler R Smyth MJ Johnstone RW The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell death pathway characterized by cleavage of Bid and production of reactive oxygen species Proc Natl Acad Sci U S A 2001 98 10833 38 11535817 Rosato RR Almenara JA Grant S The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/ WAF1 1 Cancer Res 2003 63 3637 45 12839953 Sarangi U Singh MK Abhijnya KV Reddy LP Prasad BS Pitke VV Paithankar K Sreedhar AS HSP60 chaperonin acts as barrier to pharmacologically induced oxidative stress mediated apoptosis in tumour cells with differential stress response Drug Target Insights 2013 7 35 51 10.4137/DTI.S12513 24027419 Fiskus W Ren Y Mohapatra A Bali P Mandawat A Rao R Herger B Yang Y Atadja P Wu J Bhalla K Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-A Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90 Clin Cancer Res 2007 13 4882 90 17699868 Radi R Protein tyrosine nitration: biochemical mechanisms and structural basis of its functional effects Acc Chem Res 2013 46 550 59 10.1021/ar300234c 23157446 Campanella C Caruso Bavisotto C Marino Gammazza A Nikolic D Rappa F David S Cappello F Bucchieri F Fais S Exosomal heat shock proteins as new players in tumour cell-to-cell communication J Circ Biomark 2014 3 5 10.5772/58721 Johnstone RM Exosomes biological significance: A concise review Blood Cells Mol Dis 2006 36 315 21 16487731 Cornago M Garcia-Alberich C Blasco-Angulo N Vall-Llaura N Nager M Herreros J Comella JX Sanchis D Llovera M Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe Cell Death Dis 2014 5 e1435 10.1038/cddis.2014.412 25275596 Xu XD Trends Cell Biol 2009 19 385 394 10.1016/j.tcb.2009.05.008 19648010 Khasraw M Lee A McCowatt S Kerestes Z Buyse ME Back M Kichenadasse G Ackland S Wheeler H Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial J Neuro-Oncol 2016 128 163 171 10.1007/s11060-016-2094-0 Kiss T Ecsedi S Vizkeleti L Koroknai V Emri G Kovacs N Adany R Balazs M The role of osteopontin expression in melanoma progression Tumour Biol 2015 36 7841 7847 10.1007/s13277-015-3495-y 25944164 Klingberg F Chow ML Koehler A Boo S Buscemi L Quinn TM Costell M Alman BA Genot E Hinz B Prestress in the extracellular matrix sensitizes latent TGF-beta1 for activation J Cell Biol 2014 207 283 297 10.1083/jcb.201402006 25332161 Kothari AN Arffa ML Chang V Blackwell RH Syn WK Zhang J Mi Z Kuo PC Osteopontin-A master regulator of epithelial-mesenchymal transition J Clin Med 2016 5 39 10.3390/jcm5040039 Kotobuki Y Yang L Serada S Tanemura A Yang F Nomura S Kudo A Izuhara K Murota H Fujimoto M Katayama I Naka T Periostin accelerates human malignant melanoma progression by modifying the melanoma microenvironment Pigment Cell Melanoma Res 2014 27 630 639 10.1111/pcmr.12245 24674392 Krstic J Santibanez JF Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells ScientificWorldJournal 2014 2014 521754 10.1155/2014/521754 24578639 Kulkarni AB Huh CG Becker D Geiser A Lyght M Flanders KC Roberts AB Sporn MB Ward JM Karlsson S Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death Proc Natl Acad Sci U S A 1993 90 770 774 10.1073/pnas.90.2.770 8421714 Landre V Antonov A Knight R Melino G p73 promotes glioblastoma cell invasion by directly activating POSTN (periostin) expression Oncotarget 2016 7 11785 11802 26930720 Lau LF CCN1/CYR61: the very model of a modern matricellular protein Cell Mol Life Sci 2011 68 3149 3163 10.1007/s00018-011-0778-3 21805345 Leask A Integrin 1: a mechanosignaling sensor essential for connective tissue deposition by fibroblasts Adv Wound Care 2013 2 160 166 10.1089/wound.2012.0365 Lee YH Albig AR Regner M Schiemann BJ Schiemann WP Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism Carcinogenesis 2008 29 2243 2251 10.1093/carcin/bgn199 18713838 Lenga Y Koh A Perera AS McCulloch CA Sodek J Zohar R Osteopontin expression is required for myofibroblast differentiation Circ Res 2008 102 319 327 10.1161/CIRCRESAHA.107.160408 18079410 Levy L Hill CS Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses Mol Cell Biol 2005 25 8108 8125 10.1128/MCB.25.18.8108-8125.2005 16135802 Lewis MP Lygoe KA Nystrom ML Anderson WP Speight PM Marshall JF Thomas GJ Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells Br J Cancer 2004 90 822 832 10.1038/sj.bjc.6601611 14970860 Li C Guo B Bernabeu C Kumar S Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105 Microsc Res Tech 2001 52 437 449 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G 11170303 Lin RL Zhao LJ Mechanistic basis and clinical relevance of the role of transforming growth factor-beta in cancer Cancer Biol Med 2015 12 385 393 26779375 Ludlow A Yee KO Lipman R Bronson R Weinreb P Huang X Sheppard D Lawler J Characterization of integrin beta6 and thrombospondin-1 double-null mice J Cell Mol Med 2005 9 421 437 10.1111/j.1582-4934.2005.tb00367.x 15963261 Malik R Lelkes PI Cukierman E Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer Trends Biotechnol 2015 33 230 236 10.1016/j.tibtech.2015.01.004 25708906 Mamuya FA Duncan MK aV integrins and TGF-beta-induced EMT: a circle of regulation J Cell Mol Med 2012 16 445 455 10.1111/j.1582-4934.2011.01419.x 21883891 Margadant C Sonnenberg A Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing EMBO Rep 2010 11 97 105 10.1038/embor.2009.276 20075988 Marsh D Dickinson S Neill GW Marshall JF Hart IR Thomas GJ Alpha vbeta 6 integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation Cancer Res 2008 68 3295 3303 10.1158/0008-5472.CAN-08-0174 18451156 Marsh D Suchak K Moutasim KA Vallath S Hopper C Jerjes W Upile T Kalavrezos N Violette SM Weinreb PH Chester KA Chana JS Marshall JF Hart IR Hackshaw AK Piper K Thomas GJ Stromal features are predictive of disease mortality in oral cancer patients J Pathol 2011 223 470 481 10.1002/path.2830 21294121 Martins VL Caley MP Moore K Szentpetery Z Marsh ST Murrell DF Kim MH Avari M McGrath JA Cerio R Kivisaari A Kahari VM Hodivala-Dilke K Brennan CH Chen M Marshall JF O’Toole EA Suppression of TGFbeta and angiogenesis by type VII collagen in cutaneous SCC J Natl Cancer Inst 2016 108 djv293 10.1093/jnci/djv293 26476432 Maruhashi T Kii I Saito M Kudo A Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase J Biol Chem 2010 285 13294 13303 10.1074/jbc.M109.088864 20181949 McNally A Hill GR Sparwasser T Thomas R Steptoe RJ CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis Proc Natl Acad Sci U S A 2011 108 7529 7534 10.1073/pnas.1103782108 21502514 Medici D Hay ED Goodenough DA Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelial-mesenchymal transition Mol Biol Cell 2006 17 1871 1879